Sagoo Gurdeep S, Clement Nick D, Gil-Rojas Yaneth, Bhattarai Nawaraj, Galloway Steven, Baron Jenny B, Smith Karen, Weir David J, Deehan David J
Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Edinburgh Orthopaedics, Royal Infirmary of Edinburgh, Edinburgh, UK.
Bone Jt Open. 2025 Jun 7;6(6):658-666. doi: 10.1302/2633-1462.66.BJO-2024-0274.
The aim of this study was to estimate the additional cost per quality-adjusted life-year (QALY) of robotic-assisted total knee arthroplasty (rTKA) compared to manually performed total knee arthroplasty (mTKA).
An economic evaluation was undertaken from the UK NHS and personal social services perspective, alongside a randomized controlled trial comparing rTKA and mTKA. Costs were estimated individually using a top-down approach and included all healthcare resources incurred during the trial. Costs were presented in 2021 GBP sterling (£). Responses to the EuroQol five-dimension three-level questionnaire were used to estimate QALYs for each participant. The incremental cost-effectiveness ratio (ICER) was evaluated against the current willingness-to-pay threshold recommended by the National Institute for Health and Care Excellence. Stochastic sensitivity analysis was performed using bootstrapping techniques, and results were shown through the cost-effectiveness acceptability curve and cost-effectiveness plane. Cost-effectiveness over one- and ten-year time horizons were explored using a decision model.
There were 100 participants randomized: 50 rTKA and 50 mTKA. Overall, 37 participants (39.4%) had some missing data on either costs or utilities, or on both. Multiple imputation was used for the base case results. The intervention was associated with incremental mean per-patient costs of £1,829 (95% CI 421 to 3,238) and an incremental QALY gain of 0.015 (95% CI -0.05 to 0.0796) at one year. The ICER at one year was £123,770. However, rTKA was likely to be cost-effective over a ten-year time horizon, with an ICER of £11,109. All except one of the scenarios (QALY gain reduction to 0.005) explored supported the cost-effectiveness of rTKA over a ten-year time horizon with an ICER below a £20,000 threshold.
Over a short one-year time horizon, rTKA was not a cost-effective procedure compared to mTKA. However, when results were extrapolated out to a ten-year time horizon, which would need to be confirmed in future research, rTKA was likely to be cost-effective.
本研究旨在评估机器人辅助全膝关节置换术(rTKA)相较于手动全膝关节置换术(mTKA)每质量调整生命年(QALY)的额外成本。
从英国国民健康服务体系(NHS)和个人社会服务的角度进行经济评估,同时开展一项比较rTKA和mTKA的随机对照试验。采用自上而下的方法分别估算成本,包括试验期间产生的所有医疗资源成本。成本以2021年英镑(£)表示。使用欧洲五维健康量表三级问卷的回答来估算每位参与者的QALY。根据英国国家卫生与临床优化研究所推荐的当前支付意愿阈值评估增量成本效益比(ICER)。使用自抽样技术进行随机敏感性分析,并通过成本效益可接受性曲线和成本效益平面展示结果。使用决策模型探讨一年和十年时间范围内的成本效益。
100名参与者被随机分组:50例行rTKA,50例行mTKA。总体而言,37名参与者(39.4%)在成本或效用或两者方面存在一些缺失数据。基础病例结果采用多重填补法。干预措施在一年时与每位患者的增量平均成本1829英镑(95%置信区间421至3238英镑)以及0.015的增量QALY增益(95%置信区间-0.05至0.0796)相关。一年时的ICER为123770英镑。然而,rTKA在十年时间范围内可能具有成本效益,ICER为11109英镑。除一种情况(QALY增益降至0.005)外,所有探讨的情景均支持rTKA在十年时间范围内的成本效益,其ICER低于20000英镑的阈值。
在较短的一年时间范围内,与mTKA相比,rTKA不是一种具有成本效益的手术。然而,如果将结果外推至十年时间范围(这需要在未来研究中得到证实),rTKA可能具有成本效益。